Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor
Celon Pharma S.A. recently announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint.
CPL’116 is the first-in-class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. Celon plans to initiate a multiple ascending dose Phase 1b study with safety, pharmacokinetic, and pharmacodynamic evaluations in the next coming weeks and expects readouts from this study to be available at the end of 2Q 2021.
Celon Pharma is an integrated biopharmaceutical company which designs, develops, manufactures, and distributes pharmaceutical products. It was founded in 2002 by Maciej Wieczorek, PhD. The company currently has approx. 450 employees. It employs approx. 160 scientists responsible for research and development, half of whom either have a PhD or are in the process of acquiring their PhD. The company’s pipeline includes more than a dozen projects for the development of innovative drugs with therapeutic groups such as oncology, neuro-psychiatry, autoimmunity, and metabolism. The company has its own research and development laboratories, which allow it to develop its own pharmaceutical technologies by using extensive laboratory equipment resources, as well as the experience and expertise of its staff. It also has a modern manufacturing facility where dry pharmaceutical forms are manufactured. Over the past few years, the company has introduced products into the market in the following therapeutic areas: oncology, central nervous system diseases, cardiology, HIV treatment, respiratory diseases. The company has been developing the technology for manufacturing inhalation drugs and several projects of innovative drugs since 2007. It has been listed on the Warsaw Stock Exchange since 2016. For more information, visit www.celonpharma.com.
Total Page Views: 912
